EcoDrugPlus

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSLCRG00005022084
Gene Symbol: YES1
3 Cross references
208 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSLCRG00005021593
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSLCRG00005019348
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSLCRG00005000826
Gene Symbol: LOC109137928
3 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSLCRG00005010345
Gene Symbol: ADORA1
3 Cross references
204 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSLCRG00005019975
Gene Symbol: ADORA1B
3 Cross references
173 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSLCRG00005005381
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSLCRG00005023011
Gene Symbol: ADORA2AA
3 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSLCRG00005013968
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSLCRG00005002252
Gene Symbol: ADORA3
1 Cross references
144 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSLCRG00005021007
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSLCRG00005004447
Gene Symbol: LOC109140525
2 Cross references
39 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).